| Property | Value |
|---|
|
?:abstract
|
-
PURPOSE: Veno-venous extracorporeal membrane oxygenation (V-V ECMO) is used to sustain blood oxygenation and decarboxylation in severe acute respiratory distress syndrome (ARDS) It is under debate if V-V ECMO is as appropriate for Covid-19 ARDS as it is for influenza METHODS: In this retrospective study, we analyzed all patients with confirmed SARS-CoV-2 or influenza A/B infection, ARDS and V-V ECMO, treated at our medical intensive care unit (ICU) between October 2010 and June 2020 Baseline and procedural characteristics as well as survival 30 days after ECMO cannulation were analyzed RESULTS: A total of 62 V-V ECMO patients were included (15 with COVID-19 and 47 with influenza) Both groups had similar baseline characteristics at cannulation Thirty days after ECMO cannulation, 13 3% of all patients with Covid-19 were discharged alive from our ICU compared to 44 7% with influenza (p=0 03) Patients with Covid-19 had fewer ECMO-free days (0 (0-9 7) days versus 13 2 (0-22 1) days;p=0 05) Cumulative incidences of 30-day-survival showed no significant differences (48 6% in Covid-19 patients, 63 7% in influenza patients;p=0 23) CONCLUSION: ICU treatment duration was significantly longer in ARDS patients with V-V ECMO for Covid-19 compared to influenza 30-day mortality was higher in Covid-19, but not significant
|
|
is
?:annotates
of
|
|
|
?:creator
|
|
|
?:journal
|
|
|
?:license
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
is
?:relation_isRelatedTo_publication
of
|
|
|
?:source
|
|
|
?:title
|
-
Outcome of acute respiratory distress syndrome requiring extracorporeal membrane oxygenation in Covid-19 or influenza - a single-center registry study
|
|
?:type
|
|
|
?:who_covidence_id
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}